Technical and ethical limitations in making human monoclonal antibodies (an overview)

Methods in Molecular Biology

Volumn 1060, Issue , 2014, Pages 9-36

  Glassy, Mark C ^a   Gupta, Rishab ^b  

^a Integrated Medical Sciences Association Foundation   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B cells; Clinical studies; Informed consent; Manufacturing; Natural antibodies; Recombinant antibodies

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ANTIBODY CONJUGATE; ANTIGEN; BEVACIZUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DAUNORUBICIN; DNA FRAGMENT; GANGLIOSIDE; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; PANITUMUMAB; PRITUMUMAB; PRODRUG; RADIOISOTOPE; RECOMBINANT ANTIBODY; RECOMBINANT DNA; TRASTUZUMAB; MONOCLONAL ANTIBODY;

ANTIBODY SCREENING; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; B LYMPHOCYTE; BIOETHICS; BRAIN CANCER; CANCER STEM CELL; CELL IMMORTALIZATION; CELL MIGRATION; DRUG COST; DRUG DEVELOPMENT; DRUG MANUFACTURE; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; INFORMED CONSENT; INNATE IMMUNITY; LYMPH NODE BIOPSY; PATIENT; PATIENT INFORMATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRIVACY; REVIEW; ANTIBODY SPECIFICITY; ARTICLE; IMMUNOASSAY; IMMUNOLOGY; LYMPHOCYTE; NONHUMAN; PRACTICE GUIDELINE; QUANTITATIVE ANALYSIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOTECHNOLOGY; HUMANS; PROTEIN ENGINEERING;

EID: 84931267311     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-586-6_2     Document Type: Review

References (97)

1. Teicher BA, Chari RVJ (2011) Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 17:6389-6
2. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767-7
3. Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:317-3
4. Bradbury ARM, Sidhu S, Dubel S, McCafferty J (2011) Beyond natural antibodies: the power of in vitro display technologies. Nat Biotechnol 29:245-2
5. Griffiths AD, Duncan AR (1998) Strategies for selection of antibodies by phage display. Curr Opin Biotechnol 9:102-1
6. Miraglia S, Swartzman EE, Mellentin- Michelotti J, Evangelista L, Smith C, Gunawan II, Lohman K, Goldberg EM, Manian B, Yuan PM (1999) Homogeneous cell- and beadbased assays for high throughput screening using fluorometric microvolume assay technology. J Biomol Screen 4:193-2
7. Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D, Testa JE, Quigley JP (2003) Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 22:1783-1
8. Zijlstra A, Testa JE, Quigley JP (2003) Targeting the proteome/epitome, implementation of subtractive immunization. Biochem Biophys Res Commun 303:733-7
9. Williams AF, Galfre G, Milstein C (1977) Analysis of cell surfaces by xenogeneic myeloma-hybrid antibodies: differentiation antigens of rat lymphocytes. Cell 12:663-673
10. Bernard A, Boumsell L (1984) The clusters of differentiation (CD) defined by the first international workshop on human leucocyte differentiation antigens. Hum Immunol 11:1-10
11. Hellstrom I, Garrigues HJ, Garrigues U, Hellstrom KE (1990) Highly tumor-reactive, internalizing, mouse monoclonal antibodies to Le(y)-related cell surface antigens. Cancer Res 50:2183-2190
12. Israeli RS, Powell CT, Fair WR, Heston WD (1993) Molecular cloning of a complementary DNA encoding a prostatespecific membrane antigen. Cancer Res 53:227-230
13. Carter P, Smith L, Ryan M (2004) Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 11:659-687
14. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W et al (2001) Initial sequencing and analysis of the human genome. Nature 409:860-921
15. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA et al (2001) The sequence of the human genome. Science 291:1304-1351
16. Carter P (2001) Improving the efficacy of antibody- based cancer therapies. Nat Rev Cancer 1:118-129
17. Milenic DE (2002) Monoclonal antibodybased therapy strategies: providing options for the cancer patient. Curr Pharmacol Des 8:1749-1764
18. Presta LG (2002) Engineering antibodies for therapy. Curr Pharm Biotechnol 3:237-256
19. Glennie MJ, van de Winkel JG (2003) Renaissance of cancer therapeutic antibodies. Drug Discov Today 8:503-510
20. Ross J, Gray K, Schenkein D, Greene B, Gray GS, Shulok J, Worland PJ, Celniker A, Rolfe M (2003) Antibody-based therapeutics in oncology. Expert Rev Anticancer Ther 3:107-121
21. Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20:197-216
22. Brandlein S, Vollmers HP (2004) Natural IgM antibodies, the ignored weapons in tumour immunity. Histol Histopathol 19:897-905
23. Vollmers HP, Brandlein S (2002) Natural antibodies and cancer. New Biotechnol 25:294-298
24. Bohn J (1999) Are natural antibodies involved in tumour defence? Immunol Lett 69:317-320
25. Cyster JG (1999) Chemokines and cell migration in secondary lymphoid organs. Science 286:2098-2102
26. Lapidot T et al (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645-648
27. Scadden DT (2006) The stem-cell niche as an entity of action. Nature 441:1075-1079
28. Kurosaka D, LeBien TW, Pribyl JA (1999) Comparative studies of different stromal cell microenvironments in support of human B-cell development. Exp Hematol 27:1271-1281
29. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A (2006) Human mesenchymal stem cells modulate B-cell functions. Blood 107:367-372
30. Kotlan B, Simsa P, Teillaud JL, Fridman WH, Toth J, McKnight M, Glassy MC (2005) Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumorinfiltrating B lymphocytes. J Immunol 175:2278-85
31. Westermann J, Pabst R (1992) Distribution of lymphocyte subsets and natural killer cells in the human body. Clin Investig 70:539-544
32. Koda K, Glassy MC, McKnight ME, Saito N, Dan M, Fukao K, Nakajima N (1998) Human monoclonal antibody SK-1 immunotargeting for rectal carcinoma. Int J Immunother 14:153-161
33. Koda K, Glassy MC, McKnight ME, Yasutomi J, Saito N, Dan M, Nakajima N (2001) Immuotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1. Anticancer Res 21:621-628
34. Glassy MC, McKnight M (2005) Requirements for human antibody cocktails for oncology. Expert Opin Biol Ther 5:1333-1338
35. Glassy MC, Hagiwara H (2009) Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab. Hum Antibodies 17:127-137
36. Hagiwara H, Aotsuka Y, Yamamoto Y, Miyahara J, Mitoh Y (2001) Determination of the antigen/epitope that is recognized by human monoclonal antibody CLN-IgG. Hum Antibodies 10:77-82
37. Goldsmith SJ, Signore A (2010) An overview of the diagnostic and therapeutic use of monoclonal antibodies in medicine. Q J Nucl Med Mol Imaging 54:574-581
38. Brekke OH, Loset GA (2003) New technologies in therapeutic antibody development. Curr Opin Pharmacol 3:544-550
39. Sidhu SS, Fellouse FA (2006) Synthetic therapeutic antibodies. Nat Chem Biol 2:682-688
40. Sanz L, Blanco B, Alvarez-Vallina L (2004) Antibodies and gene therapy: teaching old "magic bullets" new tricks. Trends Immunol 25:85-91
41. Chambers RS (2005) High-throughput antibody production. Curr Opin Chem Biol 9:46-50
42. Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23:1105-1116
43. Cobaugh CW, Almargo JC, Pogson M, Iverson B, Georgiou G (2008) Synthetic antibody libraries focused towards peptide ligands. J Mol Biol 378:622-633
44. Hansel TT, Kropshofer H, Singer T et al (2010) The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 9:325-338
45. Chintalacharuvu KR, Morrison SL (1995) Chimeric antibodies: production and applications. Methods 8:73-82
46. Chadd HE, Chamow SM (2001) Therapeutic antibody expression technology. Curr Opin Biotechnol 12:188-194
47. Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323-327
48. Bernett MJ, Karki S, Moore GL, Leung IW, Chen H, Pong E, Nguyen DH, Jacinto J, Zalevsky J, Muchhal US, Desjarlais JR, Lazar GA (2010) Engineering fully human monoclonal antibodies from murine variable regions. J Mol Biol 396:1474-1490
49. Norderhaug L, Olafsen T, Michaelsen TE et al (1997) Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J Immunol Methods 204:77-87
50. Kashmiri SV, De Pascalis R, Gonzales NR, Schlom J (2005) SDR grafting-a new approach to antibody humanization. Methods 36:25-34
51. Hou S, Li B, Wang L, Qian W, Zhang D, Hong X, Wang H, Guo Y (2008) Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modeling. J Biochem 144:115-120
52. Kempeni J (1999) Preliminary results of early clinical trials with the fully human anti- TNFalpha monoclonal antibody D2E7. Ann Rheum Dis 58:I70-172
53. Rau R (2002) Adalimumab: a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. Ann Rheum Dis 61:70-73
54. Ducancel F, Muller BH (2012) Molecular engineering of antibodies for therapeutic and diagnostic purposes. MAbs 4(4):445-57, PMID: 22684311
55. Stacy JE, Kausmally L, Simonsen B, Nordgard SH, Alsøe L, Michaelsen TE, Brekke OH (2003) Direct isolation of recombinant human antibodies against group B Neisseria meningitidis from scFv expression libraries. J Immunol Methods 283:247-259
56. Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NBM, Hamid M (2012). scFv antibody: principles and clinical application. Clin Dev Immunol 2012, Article ID 980250, p 15
57. Goldenberg DM (2002) Targeted therapy of cancer with radiolabeled antibodies. J Nuclear Med 43:693-713
58. Hudson PJ, Souriau C (2003) Engineered antibodies. Nature Med 9:129-134
59. Colcher D, Pavlinkova G, Beresford G, Booth BJM, Choudhury A, Batra SK (1998) Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 42:225-241
60. Hudson PJ (1999) Recombinant antibody constructs in cancer therapy. Curr Opin Immunol 11:548-557
61. Chowdhury PS, Viner JL, Beers R, Pastan I (1998) Isolation of a high-affinity stable singlechain Fv specific for mesothelin from DNAimmunized mice by phage display and construction of a recombinant immunotoxin with antitumor activity. Proc Natl Acad Sci USA 95:669-674
62. Liu SY, Eary JF, Petersdorf SH et al (1998) Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti- CD20 antibody and autologous stemcellrescue. J Clin Oncol 16:3270-3278
63. Chari RVJ (1998) Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. Adv Drug Deliv Rev 31:89-104
64. Gattenlöhner S, Jörissen H, Huhn M, et al. (2010) A human recombinant autoantibodybased immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model. J Biomed Biotechnol 2010, Article ID 187621, p 11
65. Luka J, Arlen PM, Bristol A (2011) Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC. J Biomed Biotechnol 2011, Article ID 934757, p 8
66. Gupta RK, Morton DL (2004) Prognostic utility of a glycoprotein tumor-associated antigen (TA90) specific immune complex assay in patients with cancer. Clin Appl Immunol Rev 4:395-410
67. Hoogenboom HR, Griffiths AD, Johnson KS, Chiswell DJ, Hudson P, Winter G (1991) Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acids Res 19:4133-4137
68. Griep RA, van Twisk C, Kerschbaumer RJ et al (1999) pSKAP/S: an expression vector for the production of single-chain Fv alkaline phosphatase fusion proteins. Protein Expr Purif 16:63-69
69. Durandy A (2003) Activation-induced cytidine deaminase: a dual role in class-switch recombination and somatic hypermutation. Eur J Immunol 33:2069-2073
70. Casali P, Zan H (2004) Class switching and Myc translocation: how does DNA break? Nat Immunol 5:1101-1103
71. Lieber MR, Yu K, Raghavan SC (2006) Roles of nonhomologous DNA end joining, V(D)J recombination, and class switch recombination in chromosomal translocations. DNA Repair (Amst) 5:1234-1245
72. Yan CT, Boboila C, Souza EK, Franco S, Hickernell TR, Murphy M, Gumaste S, Geyer M, Zarrin AA, Manis JP, Rajewsky K, Alt FW (2007) IgH class switching and translocations use a robust non-classical end-joining pathway. Nature 449:478-482
73. Market E, Papavasiliou FN (2003) V(D)J Recombination and the evolution of the adaptive immune system. PLoS Biol 1:e16
74. Stavnezer J, Amemiya CT (2004) Evolution of isotype switching. Semin Immunol 16:257-275
75. Rudnick SI, Adams GP (2009) Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 24:155-161
76. Glassy MC, McKnight ME (1994) Pharming the human lymph node. Exp Opin Invest Drugs 3:1057-1063
77. Glassy MC (1987) Immortalization of human lymphocytes from a tumor-involved lymph node. Cancer Res 47:5181-5188
78. Victoria GD, Nussenzweig MC (2012) Germinal centers. Ann Rev Immunol 30:429-457
79. Koda K, Nakajima N, Saito N, Yasutomi J, McKnight ME, Glassy MC (1998) A human natural antibody to adenocarcinoma that inhibits tumour cell migration. Br J Cancer 78:1313-1322
80. Kotlan B, Stroncek DF, Marincola FM (2009) Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and survival. Immunotherapy 1:995-1015
81. Giritch A, Marillonnet S, Engler C, van Eldik G, Botterman J, Klimyuk V et al (2006) Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc Natl Acad Sci USA 103:14701-14706
82. Graumann K, Premstaller A (2006) Manufacturing of recombinant therapeutic proteins in microbial systems. Biotechnol J 1:164-186
83. Borrebaeck C, Carlsson R (2001) Human therapeutic antibodies. Curr Opin Pharmacol 1:404-408
84. Chames P, Regenmortel MV, Weiss E, Baty D (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157:220-233
85. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P et al (2002) Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758
86. Weng WK, Levy R (2003) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947
87. Shinkawa T, Nakamura K, Yamane N, Shoji- Hosaka E, Kanda Y, Sakurada M et al (2003) The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibodydependent cellular cytotoxicity. J Biol Chem 278:3466-3473
88. Siberil S, Dutertre CA, Boix C, Bonnin E, Menez R, Stura E et al (2006) Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences. Immunol Lett 106:111-118
89. Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG et al (2006) Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 24:1591-1597
90. Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N et al (2006) Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 24:210-215
91. Nechansky A, Schuster M, Jost W, Siegl P, Wiederkum S, Gorr G et al (2007) Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. Mol Immunol 44:1815-1817
92. Prime W, Sobel ME, Herrington CS (2002) Utilization of human tissue in breast cancer research. Breast Cancer Res 2:237-240
93. van Diest PJ (2002) No consent should be needed for using leftover body material for scientific purposes: For and Against. Br Med J 325:648-651
94. Evans HM (2002) What's wrong with "retained organs"? Some personal reflections in the afterglow of "Alder Hey". J Clin Pathol 54:824-826
95. Malone T, Catalano PJ, O'Dwyer PJ, Giantonio B (2002) High rate of consent to bank biologic samples for future research: the Eastern cooperative oncology group experience. J Natl Cancer Inst 94:769-771
96. Schilsky RL, Dressler LM, Bucci D, Monovich L, Jewell S, Suster S et al (2002) Cooperative Group tissue banks as research resources: the Cancer and Leukemia Group B tissue repositories. Clin Cancer Res 8:943-948
97. Marshall E (2001) Families sue hospital, scientist for control of canavan gene: who controls and who benefits from human genetics research? Monash Bioeth Rev 20:50